User profiles for David L.V. Bauer
 | David LV BauerRNA Virus Replication Lab, The Francis Crick Institute Verified email at crick.ac.uk Cited by 2415 |
Neutralising antibody activity against SARS-CoV-2 VOCs B. 1.617. 2 and B. 1.351 by BNT162b2 vaccination
that emerged in the UK with the second COVID-19 wave in late 2020. The efficacy of currently
licensed COVID-19 vaccines against B. 1.617. 2 is unknown; although it possesses 12 …
licensed COVID-19 vaccines against B. 1.617. 2 is unknown; although it possesses 12 …
[HTML][HTML] Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
…, S Gandhi, S Gamblin, DLV Bauer… - Nature cancer, 2021 - nature.com
Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring
(CAPTURE) ( NCT03226886 ) is a prospective cohort study of COVID-19 immunity in …
(CAPTURE) ( NCT03226886 ) is a prospective cohort study of COVID-19 immunity in …
Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients
We sought to compare neutralising antibody responses between seronaive haemodialysis
patients and the healthy individuals we have already reported on as part of the Legacy study. …
patients and the healthy individuals we have already reported on as part of the Legacy study. …
Mini viral RNAs act as innate immune agonists during influenza virus infection
AJW Te Velthuis, JC Long, DLV Bauer, RLY Fan… - Nature …, 2018 - nature.com
The molecular processes that determine the outcome of influenza virus infection in humans
are multifactorial and involve a complex interplay between host, viral and bacterial factors 1 . …
are multifactorial and involve a complex interplay between host, viral and bacterial factors 1 . …
SARS-CoV-2 S2–targeted vaccination elicits broadly neutralizing antibodies
Several variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have
emerged during the current coronavirus disease 2019 (COVID-19) pandemic. Although …
emerged during the current coronavirus disease 2019 (COVID-19) pandemic. Although …
[HTML][HTML] AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC
The SARS-CoV-2 B. 1.617. 2 Delta variant of concern (VOC) continues to drive a sharp increase
in COVID-19 cases in the UK, with a current doubling time of 3· 5–16 days, 1 consistent …
in COVID-19 cases in the UK, with a current doubling time of 3· 5–16 days, 1 consistent …
[HTML][HTML] The structure of the influenza A virus genome
Influenza A viruses (IAVs) constitute a major threat to human health. The IAV genome consists
of eight single-stranded viral RNA segments contained in separate viral ribonucleoprotein …
of eight single-stranded viral RNA segments contained in separate viral ribonucleoprotein …
[HTML][HTML] Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer
Patients with cancer are at greater risk of severe COVID-19 and have been prioritised for
COVID-19 vaccination globally. We previously showed that following two doses of COVID-19 …
COVID-19 vaccination globally. We previously showed that following two doses of COVID-19 …
[PDF][PDF] Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer
Patients with cancer are at higher risk of severe COVID-19 (Grivas et al., 2021; Kuderer et al.,
2020), and they are currently prioritized globally for a third COVID-19 vaccine dose. …
2020), and they are currently prioritized globally for a third COVID-19 vaccine dose. …
[HTML][HTML] WHO's Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed
Elsevier, The Lancet’s publisher, con tinues to subsidise climate pollution through analytic
tools and new jour nals supporting coal, oil, and gas explo ration and extraction—an ongoing …
tools and new jour nals supporting coal, oil, and gas explo ration and extraction—an ongoing …